FDA advisory panel
org
Also written as: Food and Drug Administration advisory panel · the panel · panel
Involved in
- The FDA advisory panel recommended that compounding pharmacies be allowed to manufacture the peptides epitalon and semax, and recommended against manufacturing emideltide.
- On Friday, the panel voted 7-4 to add epitalon to the list for insomnia.
- The vote on adding semax for migraines and neurological conditions was 8-5.
- On Thursday, the panel voted 8-6 to add BPC-157 to the list for treating ulcerative colitis, to add KPV for wound healing and inflammatory conditions, and to add TB-500 for wound healing.
- The panel’s decision on Thursday recommended allowing pharmacies to make four other peptides.
- The panel’s decision brings Robert F. Kennedy Jr. one step closer to his mission of making these unapproved compounds more available for Americans.
- The article has been updated to add the vote on semax.
- The panel voted 7-5 to add MOTS-c to the list for obesity and osteoporosis.
Statements attributed to it
Nothing in the record is attributed to this entity as a speaker.
Origin: first recognised while reading FDA advisory panel narrowly rejects compounding of one peptide, backs two others · 2026-09-11 07:34